CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders acquired 4,235 call options on the company. This represents an increase of 2,705% compared to the typical daily volume of 151 call options.
Hedge Funds Weigh In On CytomX Therapeutics
A number of institutional investors have recently made changes to their positions in the business. Prosight Management LP raised its position in shares of CytomX Therapeutics by 29.2% in the 4th quarter. Prosight Management LP now owns 3,905,000 shares of the biotechnology company's stock valued at $4,022,000 after purchasing an additional 882,891 shares in the last quarter. Millennium Management LLC grew its stake in CytomX Therapeutics by 25.8% during the 4th quarter. Millennium Management LLC now owns 3,221,012 shares of the biotechnology company's stock worth $3,318,000 after buying an additional 660,756 shares during the last quarter. Point72 Asset Management L.P. bought a new position in CytomX Therapeutics during the 4th quarter worth $2,730,000. Jacobs Levy Equity Management Inc. grew its stake in CytomX Therapeutics by 1.5% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,547,215 shares of the biotechnology company's stock worth $1,594,000 after buying an additional 23,139 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in CytomX Therapeutics by 13.9% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 1,380,800 shares of the biotechnology company's stock worth $1,422,000 after buying an additional 169,000 shares during the last quarter. 67.77% of the stock is owned by institutional investors and hedge funds.
CytomX Therapeutics Stock Performance
Shares of NASDAQ:CTMX traded down $0.38 during trading on Thursday, reaching $2.00. 9,139,527 shares of the stock were exchanged, compared to its average volume of 2,056,547. CytomX Therapeutics has a 12-month low of $0.40 and a 12-month high of $2.56. The firm has a market cap of $161.24 million, a price-to-earnings ratio of 11.76 and a beta of 1.11. The firm's 50-day moving average price is $0.76 and its 200 day moving average price is $0.88.
CytomX Therapeutics (NASDAQ:CTMX - Get Free Report) last released its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.27 EPS for the quarter, topping the consensus estimate of $0.18 by $0.09. The firm had revenue of $50.92 million for the quarter, compared to analyst estimates of $35.42 million. CytomX Therapeutics had a negative return on equity of 41.47% and a net margin of 10.96%. During the same period in the previous year, the company posted $0.17 EPS. As a group, equities research analysts forecast that CytomX Therapeutics will post -0.05 EPS for the current year.
Analysts Set New Price Targets
A number of research firms recently weighed in on CTMX. Piper Sandler lifted their price objective on shares of CytomX Therapeutics from $2.50 to $5.00 and gave the company an "overweight" rating in a research report on Thursday. HC Wainwright upgraded CytomX Therapeutics from a "neutral" rating to a "buy" rating and set a $5.00 price objective for the company in a research report on Thursday. Wedbush restated an "outperform" rating and issued a $6.00 price target (up previously from $5.00) on shares of CytomX Therapeutics in a report on Monday. Finally, StockNews.com upgraded CytomX Therapeutics from a "hold" rating to a "buy" rating in a report on Tuesday.
Read Our Latest Stock Report on CTMX
About CytomX Therapeutics
(
Get Free Report)
CytomX Therapeutics, Inc, an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology.
Featured Articles
Before you consider CytomX Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CytomX Therapeutics wasn't on the list.
While CytomX Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
